Performance evaluation of a self-administered point-of-care test for anal HPV screening in PrEP users: data from a community-based PrEP service.

Human Papillomavirus Point-of-Care Testing Pre-Exposure Prophylaxis

Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
19 Apr 2024
Historique:
received: 24 07 2023
accepted: 09 03 2024
medline: 20 4 2024
pubmed: 20 4 2024
entrez: 19 4 2024
Statut: aheadofprint

Résumé

In this study, we compared the performance of a self-administered point-of-care test (POCT) for anal human papillomavirus (HPV) screening with laboratory gold-standard test in pre-exposure prophylaxis (PrEP) users and evaluated its feasibility. We enrolled PrEP users from a local community-based PrEP service. Each participant self-collected an anal swab to test anal HPV with a PCR POCT capable of detecting 14 high-risk HPV genotypes. Anonymous questionnaires on self-sampling feasibility were completed. Participants were then referred to local clinics to undergo standard viral genotyping. Concordance between POCT and gold-standard test was measured with absolute agreement and Cohen's kappa. Receiver operating characteristic (ROC) curves were used to calculate POCT sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). 179 subjects got a valid POCT result, most of them men (98.3%) and men who have sex with men (90.4%). 68.2% tested positive for at least one high-risk HPV genotype on POCT. 150 feasibility questionnaires were collected: 92.7% of compilers found the self-swab easy to perform. For 178 subjects, a gold-standard test valid result was also available: 77% tested positive for at least one high-risk HPV genotype. The median time elapsed between the two tests was 9.8 months, due to COVID-19-related service interruptions. Agreement between POCT and gold-standard test was 79.3% (Cohen's kappa=0.49). POCT showed a sensitivity of 81.0%, a specificity of 73.8%, a PPV of 91.0% and an NPV of 54.4%. POCT showed a moderate agreement with gold-standard test and a discrete sensitivity and specificity, suggesting that it could be a useful and feasible additional tool for HPV screening, especially in low-resource and community-based settings.

Identifiants

pubmed: 38641362
pii: sextrans-2023-055939
doi: 10.1136/sextrans-2023-055939
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Lorenzo Biasioli (L)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy lorenzo.biasioli@unimi.it.
Milano Check Point, Milan, Italy.

Roberto Rossotti (R)

Milano Check Point, Milan, Italy.
Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alessandro Tavelli (A)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.
Milano Check Point, Milan, Italy.

Anna De Bona (A)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.
Milano Check Point, Milan, Italy.

Camilla Tincati (C)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.

Daniele Calzavara (D)

Milano Check Point, Milan, Italy.

Pietro Vinti (P)

Milano Check Point, Milan, Italy.

Chiara Baiguera (C)

Milano Check Point, Milan, Italy.
Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Federico D'Amico (F)

Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alice Nava (A)

Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Roberto Repossi (R)

Milano Check Point, Milan, Italy.

Simona Bossolasco (S)

Milano Check Point, Milan, Italy.
Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Camilla Muccini (C)

Milano Check Point, Milan, Italy.
Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Giovanni Mulè (G)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.
Milano Check Point, Milan, Italy.

Daniele Tesoro (D)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.
Milano Check Point, Milan, Italy.

Antonella d'Arminio Monforte (A)

University of Milan, Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy.
Milano Check Point, Milan, Italy.

Classifications MeSH